Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis

被引:139
|
作者
Ajose, Olawale [2 ]
Mookerjee, Siddharth [3 ]
Mills, Edward J. [4 ]
Boulle, Andrew
Ford, Nathan [1 ,5 ]
机构
[1] Med Sans Frontieres, CH-1211 Geneva, Switzerland
[2] Clinton Hlth Access Initiat, Dar Es Salaam, Tanzania
[3] Univ London Imperial Coll Sci Technol & Med, Natl Ctr Infect Prevent & Management, London, England
[4] Univ Ottawa, Fac Hlth Sci, Ottawa, ON, Canada
[5] Univ Cape Town, Ctr Infect Dis Epidemiol & Res, ZA-7925 Cape Town, South Africa
关键词
protease inhibitors; second-line failure; viraemia; virological suppression; SUB-SAHARAN AFRICA; DRUG-RESISTANCE; ROLL-OUT; HIV; MORTALITY; EFFICACY; FAILURE; PROGRAM; COST; LOPINAVIR/RITONAVIR;
D O I
10.1097/QAD.0b013e328351f5b2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. Methods: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. Results: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. Conclusion: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure. (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:929 / 938
页数:10
相关论文
共 50 条
  • [21] Treatment Failure and Mortality Factors in Patients Receiving Second-Line HIV Therapy in Resource-Limited Countries
    Pujades-Rodriguez, Mar
    Balkan, Suna
    Arnould, Line
    Brinkhof, Martin A. W.
    Calmy, Alexandra
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (03): : 303 - 312
  • [22] First-Line Antiretroviral Therapy in Resource-Limited Settings: Time to Reconsider?
    Adlington, Rebecca
    Richens, John
    Shahmanesh, Maryam
    JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (09): : 1407 - 1407
  • [23] A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma
    Delos Santos, S.
    Udayakumar, S.
    Nguyen, A.
    Ko, Y. J.
    Berry, S.
    Doherty, M.
    Chan, K. K. W.
    CURRENT ONCOLOGY, 2020, 27 (06) : 300 - 306
  • [24] Antiretroviral therapy in the private sector of resource-limited settings
    Livesley, N
    Morris, CN
    AIDS, 2004, 18 (03) : 581 - 582
  • [25] When to Start Antiretroviral Therapy in Resource-Limited Settings
    Walensky, Rochelle P.
    Wolf, Lindsey L.
    Wood, Robin
    Fofana, Mariam O.
    Freedberg, Kenneth A.
    Martinson, Neil A.
    Paltiel, A. David
    Anglaret, Xavier
    Weinstein, Milton C.
    Losina, Elena
    ANNALS OF INTERNAL MEDICINE, 2009, 151 (03) : 157 - W38
  • [26] Second-Line Treatment for Patients With Primary Biliary Cholangitis: A Systematic Review With Network Meta-Analysis
    Giannini, Edoardo G.
    Pasta, Andrea
    Calabrese, Francesco
    Labanca, Sara
    Marenco, Simona
    Pieri, Giulia
    Torres, Maria Corina Plaz
    Strazzabosco, Mario
    LIVER INTERNATIONAL, 2025, 45 (01)
  • [27] A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment
    De Lemos-Bonotto, Michele
    Valle-Tovo, Cristiane
    Costabeber, Ane M.
    Mattos, Angelo A.
    Azeredo-da-Silva, Andre L. F.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2018, 30 (02) : 212 - 216
  • [28] Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women
    Torres, Thiago S.
    Harrison, Linda J.
    La Rosa, Alberto M.
    Cardoso, Sandra W.
    Zheng, Lu
    Ngongondo, McNeil
    Some, Fatma
    Lalloo, Umesh G.
    Mwelase, Thando
    Collier, Ann C.
    Hughes, Michael D.
    AIDS, 2018, 32 (05) : 583 - 593
  • [29] Use of antiretroviral therapy in resource-limited countries in 2006:: distribution and uptake of first- and second-line regimens
    Renaud-Thery, Francoise
    Nguimfack, Boniface Dongmo
    Vitoria, Marco
    Lee, Evan
    Graaff, Peter
    Samb, Badara
    Perriens, Joseph
    AIDS, 2007, 21 : S89 - S95
  • [30] Lopinavir/Ritonavir Monotherapy as Second-line Antiretroviral Treatment in Resource-Limited Settings: Week 104 Analysis of AIDS Clinical Trials Group (ACTG) A5230
    Kumarasamy, Nagalingeswaran
    Aga, Evgenia
    Ribaudo, Heather J.
    Wallis, Carole L.
    Katzenstein, David A.
    Stevens, Wendy S.
    Norton, Michael R.
    Klingman, Karin L.
    Hosseinipour, Mina C.
    Crump, John A.
    Supparatpinyo, Khuanchai
    Badal-Faesen, Sharlaa
    Bartlett, John A.
    CLINICAL INFECTIOUS DISEASES, 2015, 60 (10) : 1552 - 1558